[Familial pulmonary veno-occlusive disease with a composite biallelic heterozygous EIF2AK4 mutation].

Une maladie veino-occlusive pulmonaire familiale avec mutation biallélique hétérozygote composite d’EIF2AK4.
Familial Familiale Heterozygous Hypertension pulmonaire Hétérozygote Maladie veino-occlusive pulmonaire Mutation Pulmonary hypertension Pulmonary veno-occlusive disease

Journal

Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 04 06 2020
accepted: 31 08 2020
pubmed: 20 10 2020
medline: 17 12 2020
entrez: 19 10 2020
Statut: ppublish

Résumé

Pulmonary veno-occlusive disease (PVOD) is a rare cause of pulmonary hypertension. Heritable and sporadic forms have been distinguished. Hypoxemia, profound reduction in the diffusion of carbon monoxide and haemodynamic confirmation of pre-capillary pulmonary hypertension are the major diagnostic criteria. Thoracic CT scanning and a response to pharmaceutical therapy provide additional information to confirm the diagnosis. A 52-year-old patient, three of whose siblings had pulmonary hypertension, was admitted with dyspnoea, malaise and palpitations. Right heart catheterisation confirmed pre-capillary pulmonary hypertension. A search for an EIF2AK4 mutation was carried out, and this showed a composite biallelic heterozygous mutation compatible with the diagnosis of familial PVOD, identical to that showed in one of his brothers. Given the signs of severity of the disease and the diagnosis of PVOD, whose response to pharmaceutical therapy is often poor, the patient was placed on a waiting list for lung transplantation. Despite a similar diagnosis in 3 brothers and follow-up proposed 11 years before the diagnosis, pulmonary hypertension appeared within a few weeks and led immediately to a severe clinical situation. Annual clinical and echocardiographic monitoring had been strongly advised to the patient, but had not allowed diagnosis at a mild or moderate stage of the disease. This clinical case shows that the identification of factors predicting the development of heritable PVOD at a pre-symptomatic stage is an important issue for clinical research.

Identifiants

pubmed: 33071063
pii: S0761-8425(20)30284-9
doi: 10.1016/j.rmr.2020.09.004
pii:
doi:

Substances chimiques

EIF2AK4 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Case Reports Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

823-828

Informations de copyright

Copyright © 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

G Treffel (G)

Département de pneumologie, centre de compétences de l'hypertension pulmonaire, CHU de Nancy, bâtiment Philippe-Canton, rue de Morvan, 54511 Vandœuvre-lès-Nancy, France. Electronic address: gautier.treffel@laposte.net.

A Guillaumot (A)

Département de pneumologie, centre de compétences de l'hypertension pulmonaire, CHU de Nancy, bâtiment Philippe-Canton, rue de Morvan, 54511 Vandœuvre-lès-Nancy, France.

E Gomez (E)

Département de pneumologie, centre de compétences de l'hypertension pulmonaire, CHU de Nancy, bâtiment Philippe-Canton, rue de Morvan, 54511 Vandœuvre-lès-Nancy, France.

M Eyries (M)

Département de génétique, hôpital Pitié-Salpêtrière, Assistance public des Hôpitaux de Paris (AP-HP), Paris, France.

I Petit (I)

Département de radiologie, CHU de Nancy, Vandœuvre-lès-Nancy, France.

J-F Chabot (JF)

Département de pneumologie, centre de compétences de l'hypertension pulmonaire, CHU de Nancy, bâtiment Philippe-Canton, rue de Morvan, 54511 Vandœuvre-lès-Nancy, France.

A Chaouat (A)

Département de pneumologie, centre de compétences de l'hypertension pulmonaire, CHU de Nancy, bâtiment Philippe-Canton, rue de Morvan, 54511 Vandœuvre-lès-Nancy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH